Loading...
Market
Story
Pfizer and BioNTech's COVID-19-Flu Vaccine Faces Setback with 2.4% Decline
Aug 16, 2024, 01:30 PM
Pfizer and BioNTech have updated their mRNA-based combination vaccine program against influenza and COVID-19 for individuals aged 18-64. The COVID-19-flu combination drug met one of two trial objectives, but showed a lower immune response against influenza B. This setback in their late-stage trial has resulted in a 2.4% pre-market decline in BioNTech's stock. The combination vaccine's partial success highlights ongoing challenges in developing effective vaccines against multiple strains.
View original story
Similar markets
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Yes • 50%
No • 50%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Outperforms by more than 5% • 25%
Outperforms by 0% to 5% • 25%
Underperforms by 0% to 5% • 25%
Underperforms by more than 5% • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Below $100 • 25%
$100 to $120 • 25%
$120 to $140 • 25%
Above $140 • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase over 20% • 25%
Increase 10-20% • 25%
Increase less than 10% • 25%
Decrease • 25%